Search Results - Deborah Stephens

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Folliculocentric lymphocytic hypersensitivity reactions in CLL/SLL patients: A unique clinicopathologic entity amongst non‐specific hypersensitivity reactions by James Abbott, Jessica Corean, Ashley M. Snyder, Scott R. Florell, Rodney Miles, Deborah Stephens, David A. Wada

    Published in Skin Health and Disease (2023-06-01)
    Get full text
    Article


  2. 2

    P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT by Mazyar Shadman, Bhavini Srivastava, Sima Patel, Chadi Saifan, Monika Salkar, Bruno Emond, Priyanka Gogna, Ameur Manceur, Marie-Helene Lafeuille, Deborah Stephens

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  3. 3

    P644: IBRUTINIB DOSE MODIFICATIONS FOR MANAGEMENT OF CARDIAC ADVERSE EVENTS IN PATIENTS WITH B-CELL MALIGNANCIES: POOLED ANALYSIS OF 10 CLINICAL TRIALS by Deborah Stephens, Jennifer R. Brown, Shuo MA, Michael Wang, Carol Moreno, Tadeusz Robak, Don Stevens, Shane Lee, Chadi Saifan, Emily Hsu, Sima Patel, Jan Burger

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  4. 4

    P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES by Jennifer Woyach, Ian W. Flinn, Farrukh Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer Parikh, Tycel Phillips, Razi Ghori, Ima Paydar, Mohammed Z. H. Farooqui, John C. Byrd, Deborah Stephens

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


Search Tools: